Advertisement

Subcellular Renal Proximal Tubular Mitochondrial Toxicity with Tenofovir Treatment

  • James J. KohlerEmail author
  • Seyed H. Hosseini
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 755)

Abstract

Nucleoside reverse transcriptase inhibitors (NRTIs) are drugs used in the treatment of HIV/AIDS. Despite the distinct benefits of NRTI-based therapies, tissue specific toxicity is a limiting factor. Although the mechanisms of these specific antiretroviral drug-related toxicities remain unclear, it has been hypothesized that as analogs to native nucleosides, NRTIs may potentially inhibit mammalian DNA polymerases, including mitochondrial DNA (mtDNA) polymerase γ. Tenofovir disoproxil fumarate (TDF) is a nucleotide analog of adenosine monophosphate and the only NRTI that is associated with renal disease. The inherent heterogeneity of kidney tissues could affect the outcome and interpretation of molecular studies to define the mechanism(s) of tenofovir tubular toxicity. Laser-capture microdissection (LCM) provided a specific, single-cell isolation of proximal tubules from fixed heterogeneous kidney tissues. LCM-captured renal proximal tubules from transgenic mice (TGs) showed decreased mtDNA abundance with tenofovir, demonstrating a subcellular specific mitochondrial toxicity of tenofovir in an AIDS model.

Key words

NRTIs TDF Renal proximal tubules Mitochondrial toxicity Renal disease Transgenic mice mtDNA abundance 

Notes

Acknowledgments

The authors would like to thank Professor William Lewis (WL) for his advice and support and Dianne Alexis in the Pathology Core Laboratory for assistance in the histological staining and tissue section protocols. This work was supported by R01 HL79867 to WL; JK is a recipient of K01 DK78513.

References

  1. 1.
    Lewis, W., Gonzalez, B., Chomyn, A., et al. (1992) Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest 89: 1354–1360.CrossRefGoogle Scholar
  2. 2.
    Lewis, W., Grupp, I. L., Grupp, G., et al. (2000) Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 80: 187–197.CrossRefGoogle Scholar
  3. 3.
    Lewis, W. (2003) Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy. Prog Cardiovasc Dis 45: 305–318.CrossRefGoogle Scholar
  4. 4.
    Sulkowski, M. S., Mehta, S. H., Torbenson, M., et al. (2005) Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. Aids 19: 585–592.CrossRefGoogle Scholar
  5. 5.
    Lund, K. C., Peterson, L. L. & Wallace, K. B. (2007) Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother 51: 2531–2539.CrossRefGoogle Scholar
  6. 6.
    Bruggeman, L. A., Thomson, M. M., Nelson, P. J., et al. (1994) Patterns of HIV-1 mRNA expression in transgenic mice are tissue- dependent. Virology 202: 940–948.CrossRefGoogle Scholar
  7. 7.
    Lewis, W., Haase, C. P., Raidel, S. M., et al. (2001) Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Laboratory Investigation 81: 1527–1536.CrossRefGoogle Scholar
  8. 8.
    Price, C. J., George, J. D., Marr, M. C., et al. (2006) Prenatal developmental toxicity evaluation of 2′,3′-dideoxyinosine (ddI) and 2′,3′-didehydro-3′-deoxythymidine (d4T) co-administered to Swiss Albino (CD-1) mice. Birth Defects Res B Dev Reprod Toxicol 77: 207–215.CrossRefGoogle Scholar
  9. 9.
    Fux, C. A., Christen, A., Zgraggen, S., et al. (2007) Effect of tenofovir on renal glomerular and tubular function. Aids 21: 1483–1485.CrossRefGoogle Scholar
  10. 10.
    Mocroft, A., Kirk, O., Gatell, J., et al. (2007) Chronic renal failure among HIV-1-infected patients. Aids 21: 1119–1127.CrossRefGoogle Scholar
  11. 11.
    Cote, H. C., Magil, A. B., Harris, M., et al. (2006) Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 11: 79–86.Google Scholar
  12. 12.
    Vidal, F., Domingo, J. C., Guallar, J., et al. (2006) In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 50: 3824–3832.CrossRefGoogle Scholar
  13. 13.
    Birkus, G., Hajek, M., Kramata, P., et al. (2002) Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases alpha, delta, and epsilon*. Antimicrob Agents Chemother 46: 1610–1613.CrossRefGoogle Scholar
  14. 14.
    Lewis, W. (2003) Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antiviral Res 58: 189–197.CrossRefGoogle Scholar
  15. 15.
    Lewis, W., Copeland, W. C. & Day, B. (2001) Mitochondrial DNA depletion, oxidative stress and mutation: Mechanisms of nucleoside reverse transcriptase inhibitor toxicity. Laboratory Investigation 81: 777–790.CrossRefGoogle Scholar
  16. 16.
    Lyseng-Williamson, K. A., Reynolds, N. A. & Plosker, G. L. (2005) Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs 65: 413–432.CrossRefGoogle Scholar
  17. 17.
    Izzedine, H., Isnard-Bagnis, C., Hulot, J. S., et al. (2004) Renal safety of tenofovir in HIV treatment-experienced patients. Aids 18: 1074–1076.CrossRefGoogle Scholar
  18. 18.
    Schooley, R. T., Ruane, P., Myers, R. A., et al. (2002) Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16: 1257–1263.CrossRefGoogle Scholar
  19. 19.
    Padilla, S., Gutierrez, F., Masia, M., et al. (2005) Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS 19: 421–424.CrossRefGoogle Scholar
  20. 20.
    Nelson, M. R., Katlama, C., Montaner, J. S., et al. (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. Aids 21: 1273–1281.CrossRefGoogle Scholar
  21. 21.
    Barrios, A., Garcia-Benayas, T., Gonzalez-Lahoz, J., et al. (2004) Tenofovir-related nephrotoxicity in HIV-infected patients. Aids 18: 960–963.CrossRefGoogle Scholar
  22. 22.
    Breton, G., Alexandre, M., Duval, X., et al. (2004) Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1. Scand J Infect Dis 36: 527–528.CrossRefGoogle Scholar
  23. 23.
    James, C. W., Steinhaus, M. C., Szabo, S., et al. (2004) Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 24: 415–418.CrossRefGoogle Scholar
  24. 24.
    Lochet, P., Peyriere, H., Le Moing, V., et al. (2005) [Assessment of renal abnormalities in 107 HIV patients treated with tenofovir]. Therapie 60: 175–181.CrossRefGoogle Scholar
  25. 25.
    Peyriere, H., Reynes, J., Rouanet, I., et al. (2004) Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35: 269–273.CrossRefGoogle Scholar
  26. 26.
    Zimmermann, A. E., Pizzoferrato, T., Bedford, J., et al. (2006) Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 42: 283–290.CrossRefGoogle Scholar
  27. 27.
    Izzedine, H., Launay-Vacher, V., Isnard-Bagnis, C., et al. (2003) Drug-induced Fanconi’s syndrome. Am J Kidney Dis 41: 292–309.CrossRefGoogle Scholar
  28. 28.
    Dickie, P., Felser, J., Eckhaus, M., et al. (1991) HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 185: 109–119.CrossRefGoogle Scholar
  29. 29.
    Kohler, J. J., Hosseini, S. H., Hoying-Brandt, A., et al. (2009) Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 89: 513–519.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Pediatrics, Laboratory of Biochemical PharmacologyEmory University School of MedicineDecaturUSA
  2. 2.Science DepartmentGeorgia Perimeter CollegeClarkstonUSA

Personalised recommendations